Guardant Health, Inc. (GH) Earnings Call Transcripts
Guardant Health, Inc.'s Latest Earnings Call - May 12, 2026
Guardant Health, Inc. reported a strong first quarter for fiscal year 2026, leading to an upward revision of their full-year guidance. Revenue growth was driven by increased volumes in both oncology and Shield products. The company raised its guidance due to strong performance in Guardant360 and the Shield platform, with management expressing confidence in continued growth. The quarter's revenue and earnings exceeded expectations, supported by increased sales rep productivity and early positive signs from the Quest collaboration.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | Not explicitly stated (beat) |
| EPS | Not explicitly stated (beat) |
| Oncology Volume | Not explicitly stated (positive) |
| Shield Volume | Not explicitly stated (positive) |
| ASP for Shield | 7.75% (neutral) |
Guidance from management
Management raised full-year guidance due to strong Q1 performance and expected catalysts from new smart apps and Quest collaboration. They expect continued volume growth driven by increased sales rep productivity.
What management said
Yes. I would say speaking more for liquid, I think tissue is still probably too small. It's probably in the weeds in terms of exactly where that's coming from. But we're excited for really this next chapter as we get FDA approval for Guardant360 liquid as we continue to lean into therapy monitoring more. We feel it's going to be increasingly harder to use multiple sort of providers for something that you'd rather s...
What analysts pressed on
Analysts expressed concerns about the impact of the Serena 6 AdCom decision and the civil investigation in Florida. Questions focused on the implications for future opportunities and the potential impact on reimbursement dynamics.
Main topics on the call
- Revenue and Volume Growth — Guardant Health experienced strong revenue growth driven by increased oncology and Shield volumes. Management noted, 'We started Q1 very strongly and it just gives us a lot of confidence going into the rest of the year.'
- Guidance Raise — The company raised its full-year guidance based on strong Q1 performance and expected catalysts from new smart apps and Quest collaboration. 'We see a lot of catalysts on the screening side,' said the CFO.
- Therapy Monitoring — Guardant Health launched therapy monitoring, expecting it to be a significant growth area. 'We think it's going to be a pretty large indication,' noted the CEO.
- Smart Platform and AI Utilization — The smart platform continues to drive growth, with AI enhancing capabilities. 'It's been transformational for the company,' said the CEO.
Read the full Guardant Health, Inc. transcript (May 12, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Guardant Health, Inc.
Guardant Health, Inc. (GH) is a publicly listed company in the Health Care Providers and Services industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 83 calls on record spanning January 13, 2020 to September 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 83 Guardant Health, Inc. earnings call transcripts on record, spanning January 13, 2020 to September 15, 2026. Based on this history, Guardant Health, Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- GH
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Calls on record
- 83
- First call
- January 13, 2020
- Most recent
- September 15, 2026
- Reporting cadence
- quarterly